Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?

K. Khaddour; M. Ansstas; J. Visconti; G. Ansstas

doi:10.1016/j.annonc.2020.10.602

Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?

K. Khaddour
, M. Ansstas
, J. Visconti
, G. Ansstas

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	279-280
Number of pages	2
Journal	Annals of Oncology
Volume	32
Issue number	2
DOIs	https://doi.org/10.1016/j.annonc.2020.10.602
State	Published - Feb 2021

Access to Document

10.1016/j.annonc.2020.10.602

Cite this

Khaddour, K., Ansstas, M., Visconti, J., & Ansstas, G. (2021). Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? Annals of Oncology, 32(2), 279-280. https://doi.org/10.1016/j.annonc.2020.10.602

@article{2eea0102194540fe945099025a7e3e57,

title = "Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?",

author = "K. Khaddour and M. Ansstas and J. Visconti and G. Ansstas",

year = "2021",

month = feb,

doi = "10.1016/j.annonc.2020.10.602",

language = "English",

volume = "32",

pages = "279--280",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "2",

}

Khaddour, K, Ansstas, M, Visconti, J & Ansstas, G 2021, 'Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?', Annals of Oncology, vol. 32, no. 2, pp. 279-280. https://doi.org/10.1016/j.annonc.2020.10.602

Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? / Khaddour, K.; Ansstas, M.; Visconti, J. et al.
In: Annals of Oncology, Vol. 32, No. 2, 02.2021, p. 279-280.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency

T2 - any role for PARP inhibitors and checkpoint blockade?

AU - Khaddour, K.

AU - Ansstas, M.

AU - Visconti, J.

AU - Ansstas, G.

PY - 2021/2

Y1 - 2021/2

UR - https://www.scopus.com/pages/publications/85098136521

U2 - 10.1016/j.annonc.2020.10.602

DO - 10.1016/j.annonc.2020.10.602

M3 - Letter

C2 - 33308899

AN - SCOPUS:85098136521

SN - 0923-7534

VL - 32

SP - 279

EP - 280

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -

Khaddour K, Ansstas M, Visconti J, Ansstas G. Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? Annals of Oncology. 2021 Feb;32(2):279-280. doi: 10.1016/j.annonc.2020.10.602

Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?

Access to Document

Other files and links

Cite this